Skip to content

Saniona AB Sustainability Reports

Saniona AB is a clinical-stage biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders. The company leverages its proprietary ion channel drug discovery platform to develop a pipeline of therapeutics targeting rare diseases, epilepsy, and other central nervous system conditions.

Sector: Manufacturing

Country: Denmark

Exchange: Nasdaq Stockholm

LEI: 549300XO4L9XNOCFCZ84

FIGI: BBG0063H3MF7

11 reports from 2014 to 2025